BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20584002)

  • 1. Intravitreal ranibizumab treatment of retinal angiomatous proliferation.
    Kramann CA; Schöpfer K; Lorenz K; Zwiener I; Stoffelns BM; Pfeiffer N
    Acta Ophthalmol; 2012 Aug; 90(5):487-91. PubMed ID: 20584002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
    Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
    Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
    Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
    Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
    Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
    Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
    Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL
    Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
    Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
    Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
    Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
    Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.
    Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ
    Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
    Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
    Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen.
    Gharbiya M; Parisi F; Cruciani F; Bozzoni-Pantaleoni F; Pranno F; Abdolrahimzadeh S
    Retina; 2014 Feb; 34(2):298-305. PubMed ID: 23807188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.